Trexquant Investment LP grew its stake in shares of STAAR Surgical Company (NASDAQ:STAA) by 79.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,716 shares of the medical instruments supplier’s stock after buying an additional 8,727 shares during the period. Trexquant Investment LP’s holdings in STAAR Surgical were worth $245,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Palo Alto Investors LLC increased its position in STAAR Surgical by 1.6% during the second quarter. Palo Alto Investors LLC now owns 3,529,070 shares of the medical instruments supplier’s stock worth $38,114,000 after buying an additional 55,900 shares in the last quarter. Vanguard Group Inc. increased its position in STAAR Surgical by 0.6% during the second quarter. Vanguard Group Inc. now owns 1,280,775 shares of the medical instruments supplier’s stock worth $13,832,000 after buying an additional 7,803 shares in the last quarter. Baillie Gifford & Co. increased its position in STAAR Surgical by 4.8% during the third quarter. Baillie Gifford & Co. now owns 698,742 shares of the medical instruments supplier’s stock worth $8,699,000 after buying an additional 32,130 shares in the last quarter. State Street Corp increased its position in STAAR Surgical by 7.8% during the second quarter. State Street Corp now owns 684,125 shares of the medical instruments supplier’s stock worth $7,390,000 after buying an additional 49,362 shares in the last quarter. Finally, Northern Trust Corp increased its position in STAAR Surgical by 5.2% during the second quarter. Northern Trust Corp now owns 481,459 shares of the medical instruments supplier’s stock worth $5,199,000 after buying an additional 23,764 shares in the last quarter. 77.73% of the stock is owned by institutional investors.

STAA has been the subject of several recent research reports. Canaccord Genuity reissued a “buy” rating and set a $15.00 price target on shares of STAAR Surgical in a research report on Sunday, October 8th. Zacks Investment Research raised STAAR Surgical from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Saturday, September 23rd. Benchmark reissued a “buy” rating and set a $21.00 price target on shares of STAAR Surgical in a research report on Monday, November 20th. TheStreet raised STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday, August 15th. Finally, BidaskClub raised STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. STAAR Surgical has an average rating of “Buy” and a consensus target price of $17.67.

Shares of STAAR Surgical Company (NASDAQ:STAA) opened at $16.85 on Friday. The company has a current ratio of 2.24, a quick ratio of 1.72 and a debt-to-equity ratio of 0.02. STAAR Surgical Company has a 1 year low of $8.95 and a 1 year high of $17.60.

In other news, VP Keith Holliday sold 6,000 shares of STAAR Surgical stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total value of $99,900.00. Following the completion of the sale, the vice president now owns 45,969 shares of the company’s stock, valued at $765,383.85. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.60% of the stock is owned by insiders.

WARNING: “STAAR Surgical Company (STAA) Shares Bought by Trexquant Investment LP” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/staar-surgical-company-staa-shares-bought-by-trexquant-investment-lp/1751199.html.

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical Company (NASDAQ:STAA).

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.